Method of treating periodontitis and oral mucosal diseases associated with helicobacter infection, and method for using it

FIELD: medicine.

SUBSTANCE: agent for treating inflammatory periodontal and oral mucosal diseases associated with Helicobacter infection contains silicone glycerohydrogel of Si(C3H7O3)4·6C3H8O3·24H2O and bismuthate tripotassium dicitrate of formula [HOC(CH2COO)2COO]2K3Bi in the following proportions, wt %: bismuthate tripotassium dicitrate 1.0-2.5; silicone glycerohydrogel - the rest up to 100. The method of treating inflammatory periodontal and oral mucosal diseases consists in a combination of systemic standard anti-Helicobacter therapy and a local effect of the above agent on the involved region. Particularly, treating periodontitis is ensured by applying the agent on the gingival surface and introducing it into the gingival pockets once a day for 10 min; the therapeutic course makes 5-6 days. The oral mucosal diseases are treated by applying the agent 0.1 mm thick with a glass spatula on the involved oral mucosa 2 times a day; the therapeutic course is 12 days.

EFFECT: formulation of the agent provides achieving the high therapeutic effect; the dosage form is easy to be applied locally.

4 cl, 2 dwg, 1 tbl, 2 ex

 

The invention relates to medicine, namely to dentistry, and can be used for treatment of inflammatory and degenerative diseases and periodontal diseases of the oral mucosa associated with Helicobacter infection (Helicobacter pylori).

At the present time the attention of gastroenterologists and dentists facing the cavity of the mouth as a permanent reservoir for the persistence of the microorganism Helicobacter pylori, which is found in more than 95% of patients suffering from peptic ulcer of the duodenum, in 70-80% of those with gastric ulcer and in 60-70% of cases of gastric cancer [Medical Microbiology, Virology and immunology: a Textbook / ed. - M: Medical information Agency, 2004. - 69 p.].

However it is proved that the biotopes of the mouth, which drives Helicobacter pylori, not just cause of gastroduodenal pathologies, but also can be causing, worsening of the clinical course and low effectiveness of treatment of inflammatory diseases of periodontal tissues and diseases of the oral mucosa [Chobanov R. E., Mamedov R. M. Peculiarities of settlement of different Sabitov oral Protozoa and Helicobacter pylori in inflammatory periodontal disease / Periodontics, volume XV, 3(56), 2010. - Pp. 29-30].

Therefore, treatment of Helicobacter pylori - associated periodontitis and disease�s oral mucosa, is one of the important and complex public health problem with medical and socio-economic significance.

The known method of eradication of Helicobacter pylori in periodontal tissues, including standard oral drug eradication therapy on the recommendations of the Consensus "Maastricht-3 and with the additional impact on periodontal tissues infrared laser radiation with the simultaneous influence of non-stationary alternating magnetic field within 5-7 minutes daily, 10-15 sessions per course (patent RF №2394617). The method may be implemented using an integrated magnetic-laser therapy, containing the source IKLI with a controlled repetition rate, sources stationary and non-stationary magnetic fields. The invention allows to reduce terms of treatment of periodontitis and to achieve a sustained remission of the disease through a combination of local and systemic eradication of Helicobacter pylori, reduction parodontopathogenic species of microorganisms, to restore the functional activity of the epithelial cells of the gums. The disadvantages of this method is its complexity, the need for special equipment for its implementation, outstanding efficacy in the treatment of diseases of the oral mucosa.

The known method where the patients for the treatment of inflammatory for�of olivani periodontal on the background of chronic gastritis with Helicobacter eradication of Helicobacter pylori in the oral cavity prescribed rinsing rinse "Asepta" 2 times daily after brushing and the application of the adhesive gel "Asepta" 2 times a day for 10 days with metronidazole and chlorhexidine [Osipov Yu. L., Bulkina N. In. Especially the effectiveness of eradication therapy in patients with inflammatory periodontal diseases on the background of chronic Helicobacter gastritis // Saratov scientific medical journal, 2011, volume 7, No. 1, Pp. 282-284). A positive result of the method is 95% no persistence of Helicobacter pylori in the oral cavity. The disadvantage of this method is that use products containing metronidazole which provides immunomodulate action, and chlorhexidine, which leads to discoloration of the teeth (the darkening). In addition, there are data on the development of resistance of Helicobacter pylori to metronidazole [Mayev I. V., Samsonov A. A., Andreev D. N., Kochetov, S. A. the Evolution of ideas about the diagnosis and treatment of Helicobacter pylory (based on consensus Maastrich IV, Florence, 2010) // Bulletin of the practitioner. Special issue 1, 2012]. It should also be noted that antibiotic therapy is a modern medical forms used in the treatment of periodontal diseases, long and vysokozatratno.

A method of treating patients with inflammatory periodontal diseases on the background of gastric ulcer with the simultaneous conduct of oral H. pylori eradication therapy prescribed prepar�t lactobacilli koumiss lyophilized (cellulose, magnesium stearate, microcrystalline cellulose) (patent RF 2316218) "Mare-Forte 0.6 g No. 60 1 tablet 2 times a day for 30 days in combination with local application of sterile turund, pre-impregnated with a prepared solution of De-Nol, active substance is bismuth subcitrate potassium, prepared by the following procedure: in a beaker in 10 ml of distilled water at room temperature was dissolved 1 tablet (120 mg) De-Nol, pre-powdered, for 15 minutes in 4 weeks [Bashirova T. V. Optimization of treatment of gingivitis and periodontitis in patients with gastric ulcer associated with Helicobacter pylori infection/ author. Diss. MD - Ufa. - 2012. [4] (prototype).

This method provides for the eradication of Helicobacter pylori in periodontal tissues, reduces the level of pathogenic microorganisms in the oral cavity and to improve the clinical results of treatment of periodontitis in patients with gastric ulcer associated with Helicobacter pylori infection. The disadvantages of this method is its complexity, duration, high cost of treatment. Lactobacilli may contribute to belascoaran and development of multiple dental caries.

Thus, there is a need to develop a method of treatment of periodontitis and diseases of the oral mucosa associated with Helicobacter�world infection of the body, using the new low-toxicity specific funds.

The technical result consists in the fact that developed specific means of convenient form for topical application, allowing to achieve a high therapeutic effect with the use of active drug additives bismuth tripotassium dicitrate formula [HOC(CH2COO)2COO]2K3Bi and hydrophilic bases - silicone glycerokinase composition Si(C3H7O3)4·6C3H8O3·24H2O.

Stated agent for the treatment of periodontitis and diseases of the oral mucosa associated with Helicobacter infection, including active bismuth tripotassium dinitrocresol medicinal additive and a hydrophilic base, characterized in that the hydrophilic bases it contains silicone glycerokinase composition Si(C3H7O3)4·6C3N8O3·24H2O and bismuth subcitrate potassium formula [HOC(CH2COO)2COO]2K3Bi in the following ratio of components, wt.%:

- bismuth subcitrate potassium 1,0-2,5;

- silicone glycerokinase - the rest is up to 100.0.

Claimed is also a method of treatment of inflammatory periodontal diseases and diseases of the oral mucosa associated with Helicobacter infection involving simultaneous holding system standard H. pylori eradication therapy and local effects of the drug on the area affected area by application on the gingival surface or installation in periodontal pockets, characterized in that the use of the claimed remedy that is applied on the gingival surface or injected into periodontal pockets once a day for 10 min for the treatment of periodontitis, treatment 5-6 days; or put a glass spatula a thin layer of a thickness of 0.1 mm to the lesion of the mucous membranes of the mouth, 2 times a day, treatment course of 12 days.

As a result of the action of bismuth tripotassium dicitrate is the destruction of the cytoplasmic membrane of bacteria, the bacteria lose their adhesion to the epithelial cells of the patient and develops apoptosis in Helicobacter pylori. As a result of the use of silicone glycerokinase are conditions for reducing the concentration of a specific drug (bismuth tripotassium dicitrate), in force on Helicobacter pylori.

Currently, the scientific-technical and patent literature known local tool and method for treatment of inflammatory periodontal diseases and diseases of the oral mucosa associated with Helicobacter infection, comprising as an active additive bismuth subcitrate potassium formula [HOC(CH2COO)2COO]2K3Bi, and as hydrophilic bases of organic silicon glycerokinase composition Si(C3H7O3)4·6C3H8O3·24H2O and brushless�creating a set of proposed components in the claimed limits of their content.

As a medicinal Supplement for eradication of Helicobacter pylori in the oral cavity in the proposed tool use bismuth subcitrate potassium formula [HOC(CH2COO)2COO]2K3Bi, one of the main characteristics of which is its bactericidal effect on Helicobacter pylori. Bismuth subcitrate potassium inhibits the enzymes of Helicobacter pylori: urease, catalase, phospholipase and proteolytic activity. As a result of the complex effects of bismuth tripotassium dicitrate comes lysis of bacterial cells in the vicinity of the epithelium of the oral mucosa. It is very important that the bismuth tripotassium dicitrate is able to influence both at vegetative and coccoid forms of Helicobacter pylori, which most often detected in the oral cavity.

In the proposed tool bismuth subcitrate potassium formula [HOC(CH2COO)2COO]2K3Bi is used in powder form in a concentration range of 1.0-2.5 wt.%.

The presence in the composition of the pharmaceutical compositions of organosilicon glycerokinase with high regenerative transcutaneous activity (patent RF №2255939), can significantly increase the effectiveness of treatment and to reduce the period of time. Silicone glycerokinase composition Si(C3H7O3)4·6C3H8O3·24H2O non-toxic, protects the tissue from drying out and OTE�s, increases oxygenation, does not require preservatives, structurally compatible with the lipid component of cell membranes. In addition, the presence of essential element silicon has been actively stimulating effect on all types of tissue: epithelial, connective, bone, and contributes to a proceeding in which the proliferative one-reparative processes, improves vitality, increases blood circulation.

The conducted research allows to draw the conclusion that only with the use of bismuth tripotassium dicitrate and silicone glycerokinase in the claimed limits of ratio can be achieved a high efficiency of treatment with a significant reduction of terms.

Studies have shown good compatibility bismuth tripotassium dicitrate and silicone glycomolecules and helped to identify the limits of their quantitative content in the tool, providing a manifestation of the maximum therapeutic effect. So, when the content of bismuth tripotassium dicitrate is less than 1.0 wt.% a slowdown of the existence of a therapeutic effect. The increase in the content of bismuth tripotassium dicitrate more than 2.5 wt.% it is impractical because of the increasing probability of physico-chemical incompatibilities, deterioration of the stability of the funds and its appreciation, as well as the likelihood of side �negative phenomena.

Thus, the qualitative and quantitative composition the proposed remedies provides pharmaceutical and pharmacological compatibility and, as a consequence, a high therapeutic effect.

Fig.1 shows the condition of the oral mucosa with exudative-hyperemic the lichen planus before treatment.

Fig.2 shows the condition of the oral mucosa after treatment with the claimed drug.

The proposed product is prepared as follows. Take organosilicon glycerokinase of a transparent or translucent colorless gel, odorless, stable under storage conditions, the composition Si(C3H7O3)4·6C3H8O3·24H2O. Add powdered bismuth subcitrate potassium formula [HOC(CH2COO)2COO]2K3Bi at a weight ratio (wt.%): bismuth tripotassium dicitrate is 1.0-2.5 and silicone glycerokinase to 100.0. The mixture was thoroughly stirred at room temperature for 10-15 min in a rotary type mixer (homogenizer). Get ready to use the tool for local use white color, soft consistency.

The proposed technical solution is illustrated by the following examples.

Example 1. Take of 97.5 g of silicone glycerokinase composition Si(C3H O3)4·6C3H3O3·24H2O representing translucent colorless gel, odorless, stable under storage. Add 2.5 g of bismuth tripotassium dicitrate formula [HOC(CH2COO)2COO]2K3Bi. The mixture was thoroughly stirred in a rotary type mixer at room temperature for 15 min. Get ready to use the ointment soft consistency with the following ratio of components, wt.%: bismuth subcitrate potassium 2,5; silicone glycerokinase - of 97.5. Ointment meets the requirements for a pharmaceutical agent for topical use.

Example 2. Take 99,0 g of silicone glycerokinase composition Si(C3H7O3)4·6C3H8O3·24H2O representing translucent colorless gel, odorless, stable under storage. Add 1.0 g of bismuth tripotassium dicitrate formula [HOC(CH2COO)2COO]2K3Bi. The mixture was thoroughly stirred in a rotary type mixer at room temperature for 15 min. Get ready to use the ointment soft consistency with the following ratio of components, wt.%: bismuth tripotassium dicitrate - 1,0; silicone glycerokinase - 99,0. Ointment meets the requirements for a pharmaceutical agent for topical use.

The facilities on offer� used as follows. In combination with integrated traditional therapy of periodontitis proposed tool is applied by application to the gingival surface, or by installations is administered into periodontal pockets for diseases of periodontal tissues; or put a small glass with a spatula in a thin layer with thickness of 0.1 mm to the lesion of the oral mucosa.

Procedure while holding system standard H. pylori eradication therapy is repeated every day once a day for 5-6 days for the treatment of diseases of periodontal tissues and 2 times a day for 12 days for the treatment of diseases of the oral mucosa associated with Helicobacter infection.

Examples of use of the claimed medicinal product.

Example 1. Patient P., born in 1961 appealed with complaints of bleeding gums, pain, swelling. In history - duodenal ulcer associated with Helicobacter infection.

The diagnosis of chronic generalized periodontitis mild severity. The diagnosis was made on the basis of complaints, anamnesis, objective data, radiological, and microbiological research.

Objectively gums are swollen, there are solid dental plaque, periodontal pockets and 3.5 mm. Mobility 4.1, 4.2, 3.2, 3.1 teeth I degree. Indexes: IG (oral hygiene index of Greene-Vermillion)=2,2; PMA (papillare-�orginalna-alveolar index)=32%; bleeding second degree. Orthopantomogram - bone resorption 1/3 the length of the root in the mental Department. Rapid urease test is positive by microscopy of smears detected Helicobacter pylori (test material - the contents of periodontal pockets).

The patient as a topical treatment was prescribed the claimed medicinal product (example 2) day 1 every day for 5 days in combination with integrated traditional treatment of periodontitis and systemic standard H. pylori eradication therapy. The inventive medicament is applied on the gingival surface and injected into affected teeth periodontal pockets. Allowed to stand for 10 minutes and remove. Repeat daily 1 time per day for 5 days. Indicators after treatment: mucosa is pale pink, painless on palpation, periodontal pockets of 3 mm. Mobility I art Indexes: IG=1,4; PMA=6,6%; no bleeding. On the radiograph is determined by the resorption of interdental septa to 1/3 the length of the root. Persistence of Helicobacter pylori in the oral cavity according to the study contents of periodontal pockets by microscopii smears and rapid urease test were not revealed.

Example 2. Patient M. L., 1964 R. appealed with complaints of halitosis, suppuration, profuse Tartar. In history - ulcer ventricles�ka, associated with Helicobacter infection.

The diagnosis of chronic generalized moderate periodontitis in the acute stage. The diagnosis was made on the basis of complaints, anamnesis, objective data, radiological, and microbiological research.

Objectively gums are hyperemic, edematous, there are hard dental deposits, suppuration, gingival pockets - 4.5 mm. the Mobility of I-II degree. Indexes: IG (oral hygiene index of Greene-Vermillion)=2,7; PMA (papillare-marginal-alveolar index)=45,4%; bleeding 3 degrees. Orthopantomogram - determined resorption of interdental septa 1/2 the length of the root. Rapid urease test is positive by microscopy of smears detected Helicobacter pylori (test material - the contents of periodontal pockets).

The patient as a topical treatment was prescribed the claimed medicinal product (example 1) daily 1 time per day for 6 days in combination with standard eradication therapy and integrated traditional treatment of periodontitis. The inventive product is applied on the gingival surface and injected into affected teeth periodontal pockets. Allowed to stand for 10 minutes and remove. Repeat daily 1 time per day for 6 days. Indicators after treatment: mucosa is pale pink, wet, shiny, periodontal�pockets-date - 4 mm Mobility II of article Indexes: IG=1,8; PMA=7,1%; no bleeding. On the radiograph is determined by the resorption of interdental septa 1/2 the length of the root. Persistence of Helicobacter pylori in the oral cavity according to the study contents of periodontal pockets by microscopy of smears and rapid urease test were not revealed.

These examples illustrate the use of this remedies for the treatment of periodontitis associated with Helicobacter infection.

For the treatment of diseases of the oral mucosa associated with Helicobacter infection, the lesion is applied in a thin layer of the claimed medicinal product, the thickness of which is 0.1 mm. the Application of drugs by a small glass spatula. To improve therapeutic effect is recommended within one hour of not eating. Drug composition is used twice a day, the treatment lasts for 12 days.

The claimed medicinal product used for the treatment of 17 patients with lichen planus of the oral mucosa with a history of stomach ulcer, associated with Helicobacter pylori infection. One is the 11 - erosive-ulcerous form 6 - exudative-hyperemic form. The treatment efficiency was evaluated in the dynamics of subjective symptoms and clinical picture.

P�emer No. 3. Patient O. complained of a burning sensation and pain in the mouth, worse when hot, spicy food. History - peptic ulcer, associated with Helicobacter infection.

Objectively: the mucous membrane of the cheeks multiple papular elements grayish-white color, merge to form a mesh pattern, mucous giperimirovana slightly swollen, painful on palpation.

Diagnosis: lichen planus - exudative-hyperemic form (Fig.1). The diagnosis was made on the basis of complaints, anamnesis, objective data, histological examination.

The patient as a topical treatment was prescribed the claimed medicinal product (example 2), 2 times a day for 12 days in conjunction with the overall treatment system and standard H. pylori eradication therapy. After the first day of the drug significantly decreased soreness in the mouth, on the 3rd day the pain disappeared on the 5th day of treatment there was a change in the clinical picture in the direction of reduce inflammation (decreased redness, swelling). After the end of treatment, the patient no complaints, the mucous membrane of the mouth pale pink in color, moist, are stored in single papules without signs of inflammation. Persistence of Helicobacter pylori in the oral cavity by microscopy of smears with about�yeah lesions were not detected (Fig.2).

Example No. 4. Patient G. complained to the presence of erosion under the tongue, pain when eating. Objectively: the mucous membrane of the sublingual area to the left, closer to bridle the tongue, hyperemic, edematous with multiple papular elements, grayish-white color, which merge to form a mesh pattern, a violation of the integrity of the mucosa, erosion, covered with bloom, painful on palpation. History - peptic ulcer, associated with Helicobacter infection.

Diagnosis: lichen planus erosive-ulcerative form. The diagnosis was made on the basis of complaints, anamnesis, objective data, histological examination.

In conjunction with the overall treatment system and standard H. pylori eradication therapy as local treatment was assigned to the claimed medicinal product (example 1), 2 times a day for 12 days.

As a result of treatment after the first day the drug became much less painful when eating, on day 4, the pain disappeared, erosion cleared of plaque. On the 5th day of treatment there was a decrease of hyperemia, edema, erosion had no plaque, began epithelialization of the peripheral part of the erosion. On the 12th day epithelialization was observed erosion, the mucous membrane of the mouth pale pink in color, moist, single papules without recognized�s of inflammation flattened. Persistence of Helicobacter pylori in the oral cavity by microscopy of smears from the lesion is not identified.

The proposed tool was tested in the dental clinic at the Tyumen state medical Academy on volunteers in the conservative treatment of periodontal inflammatory diseases associated with Helicobacter infection, and in the clinic of therapeutic stomatology of the Ural state medical University for the treatment of diseases of the oral mucosa associated with Helicobacter infection. After the course of treatment proposed by the agent in microbiological study of Helicobacter pylori in the oral cavity was not determined. The advantages of the proposed drug in comparison with the prototype presented in table 1.

Table 1. Clinical evaluation of the effectiveness of the stated funds in comparison with the prototype

Clinical evaluation of the effectiveness of the proposed remedies for the treatment of inflammatory and degenerative diseases and periodontal diseases of the oral mucosa caused by Helicobacter infection (Helicobacter pylori) in comparison with the prototype showed a higher therapeutic effect and lower time costs to achieve it.

The proposed remedy for the treatment of periodontitis and zabolevaniiami membranes of the mouth, associated with Helicobacter infection, it is convenient for local application, allows to achieve a high therapeutic effect. Transcutaneous activity hydrophilic bases not only make use of small concentrations of active drug additives, but also leads to deeper penetration of the specific drug in diseased tissue.

The overall economic effect in the treatment of, for example, periodontitis associated with Helicobacter infection, 100 patients in comparison with the prototype is 300,000 rubles.

1. Agent for the treatment of periodontitis and diseases of the oral mucosa associated with Helicobacter infection, including active bismuth tripotassium dinitrocresol medicinal additive and a hydrophilic base, characterized in that the hydrophilic bases it contains silicone glycerokinase composition Si(C3N7O3)4·6C3N8O3·24H2O and bismuth subcitrate potassium formula [NOSE(CH2COO)2COO]2K3Bi in the following ratio of components, wt.%:
bismuth tripotassium dicitrate 1,0-2,5;
silicone glycerokinase - the rest is up to 100.0.

2. Method of treatment of inflammatory periodontal diseases and diseases of the oral mucosa associated with Helicobacter infect�her involving simultaneous holding system standard H. pylori eradication therapy and local effects of the drug on the area affected area, characterized in that applying a compound according to claim 1.

3. A method according to claim 2, characterized in that for the treatment of periodontitis tool according to claim 1 is applied on the gingival surface and injected into periodontal pockets once a day for 10 minutes, the course of treatment 5-6 days.

4. A method according to claim 2, characterized in that for the treatment of diseases of the oral mucosa a compound according to claim 1 is applied to a glass spatula a thin layer of a thickness of 0.1 mm to the lesion of the mucous membranes of the mouth, 2 times a day, treatment course of 12 days.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method includes the preparation of a carious cavity, opening the tooth cavity, creation of an access to root canals, extension of their orifice. Removal of a decayed material from the root canals and their drug treatment are carried out. After that, performed are: wide opening of the apical tooth orifice, mechanical and drug removal of periapical pathological exudative formations in the focus of periapical inflammation through the root canal. Before filling the canal with a filling material the gel "Lamifaren" is introduced into the focus of periapical destruction. Such introduction is performed three times after a day under temporary stopping. The gel "Lamifaren" is introduced inside in a dose of 50 g 2 times per day for 30 days.

EFFECT: application of the invention accelerates bone tissue regeneration due to the active release of an active substance calcium alginate, provides stable remission due to local and systemic detoxifying effect.

2 ex

FIELD: medicine.

SUBSTANCE: treatment is two-staged; at the first stage, gingival pockets are rinsed with a stream of 1.5% hydrogen peroxide in a cannula delivered through the gingival pockets around the teeth. If observing the exposed furcation of premolars and molars, the cannula is brought under the root furcation. Thereafter, the gingival pockets are similarly rinsed with an aqueous tincture of garden sage herb for 3-5 days, then with an aqueous tincture of camomile blossom for 3-5 days, an aqueous tincture of plantain leaves daily for the following 3-5 days; each rinsing procedure is followed by applications of cotton drains impregnated with the respective aqueous herbal tincture introduced by the cannula on gingival mucous membranes for 1 hour; that is combined with prescribing oral baths with the respective aqueous herbal tincture introduced by the cannula daily 5-7 times a day. The second stage involves instillations of Normoflorin-B or Bifidumbacterin in the cannula delivered through the gingival pockets around the teeth, brought under the furcation if observing the exposed furcation of premolars and molars; the gingival mucous membranes are laid with cotton drains with the above preparation for 2 hours daily for 5-10 days.

EFFECT: method enables providing the higher clinical effectiveness.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: at the first stage, after removing supra- and sub-gingival dental calculus and granulations, cleaning the teeth professionally, rinsing gingival pockets by stream infusions of 1.5% hydrogen peroxide in a cannula delivered through the gingival pockets around the teeth, brought under root furcation if observing the exposed furcation of premolars and molars; the preparation "Calsept" is administered within the frontal teeth for 5-7 days daily into the gingival pockets bringing the cannula similarly around the teeth, whereas the preparation "Calsept-Iodo" is administered within the distal teeth; the dentist recommends that the patient does not eat for 2 hours thereafter. The second stage involves administering a preparation containing bifidus bacteria, e.g. Normoflorin-B or Bifidumbacterin by instillations in a cannula delivered through the gingival pockets around the teeth, brought under the furcation if observing the exposed furcation of premolars and molars; gingival mucous membranes are laid with cotton drains with the preparation for 2 hours daily for 5-10 days.

EFFECT: using the method provides increasing the therapeutic effect ensured by the antibacterial effect, odontotropic and anaesthetic action, bone tissue recovery, action of the therapeutic preparation in difficult-to-access anatomic formations.

2 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to health-promoting compositions and methods for preparing them. A method for preparing the composition of non-living lactic acid bacilli, possessing an ability of specific binding to Streptococcus mutans, involves the following stages: heating a cell suspension of lactic acid bacillus or a mixture of lactic acid bacilli possessing an ability of specific binding to Streptococcus mutans from an initial temperature of less than 40°C to a pasteurisation temperature of 75 to 85°C with a temperature variation within the range of 0.5 to 2°C/min, keeping the heated suspension at a pasteurisation temperature of 20 to 40 minutes and cooling the suspension to a final temperature of less than 40°C within the range of 0.5 to 2°C/min. The specific binding the cell suspension of the lactic acid bacillus or the mixture of lactic acid bacilli to Streptococcus mutans is stable to heat treatment and/or resistant to proteases and/or calcium-dependent and/or is observed within the range of pH values falling within the range of 4.5 and 8.5, and/or in the saliva environment.

EFFECT: invention enables producing the agent preventing or delaying the caries lesion formation.

9 cl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to oral care compositions containing a basic amino acid or its salt. The presented oral care composition promoting the dentine defect closure in the oral cavity contains arginine in the free form or in the form of a salt, and an abrasive substance representing synthetic amorphous silica and containing small particle fractures making at least approximately 5% of total weight of the composition, wherein the particles of the small particle fracture having d50 from 3 to 4 mcm. What is also presented is a method of treating sensitive teeth in the oral cavity involving using the oral treatment with this composition, as well as using arginine as a part of the oral care composition and for producing a therapeutic agent, wherein the above composition and agent contain the above abrasive material containing the small particle fracture.

EFFECT: group of inventions provide the effective dentin defect closure in the patient's oral cavity.

8 cl, 1 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: carious cavity is prepared. Then it is treated instrumentally and antiseptically. A hole of an apical canal of a causative tooth is expanded. Methylene blue is introduced into the cyst through a root canal at a depth of 7-10 min. The cyst envelope is exposed to a laser light generated by a diode laser through the root canal for 30-60 s by means of a needle light guide. The exposure is continued from the vestibular or oral surface for 60.0-120.0 s by means of a plate light guide of intensity 0.5-1 W, wave length 625-630 nm in a pulse mode. Before the root canals of the causative tooth is hermetically sealed, Collap-An gel with metrogil 1.0-1.5 ml is introduced into the cyst.

EFFECT: method enables provides increasing clinical effectiveness, avoiding the complications by removing the cyst envelope completely that enables restoring the bone defect structure completely.

2 ex

FIELD: medicine.

SUBSTANCE: agent for local therapy of recurrent oral aphthae accompanying dental stomatitis and periodontitis contains glycerine, kalanchoe juice and common nettle juice, glucosamine hydrochloride and dimethylsulphoxide, lavender, common thyme, garden sage and pepper mint essences, lime blossom and drinking water in a certain ratio.

EFFECT: agent possesses anti-inflammatory, antibacterial, wound healing, haemostatic, local anaesthetic, saliva thinning properties enabling its effective use for combined periodontal and oral mucosal pathologies in the form of dental stomatitis and periodontitis, including if observing deep periodontal pockets.

3 ex

FIELD: medicine.

SUBSTANCE: first, the method involves teeth cleaning, surgical site isolation with cotton swabs, drug-induced treatment of 2% chlorhexidine and drying. Then, an erosion surface and adjoining solid dental tissues are coated with a phytoapipreparation for 15-20 minutes. The preparation is presented in the form of an ointment and has the following composition, weight fractions: 40% alcoholate (1:10) of tartarian catchfly or rhizomes and roots of maral root 10 ml, 40% alcoholate (1:10) of spirea herb 5 ml, apilac 0.5 g, clove ester 0.5 ml, lanolin 25.2 g, Vaselin 58.8 g. The ointment is used once a day for 10 days with the patients advised to avoid eating for one hour.

EFFECT: method is easy-to-use and physiological, and ensures an absolute recovery.

2 ex

FIELD: medicine.

SUBSTANCE: performing a dental intervention in the patients suffering an acute stroke requires the oral administration or injections of a broad-spectrum antibiotic after examining the mouth or determining the extent of the dental intervention extent 30-60 minutes before the expected intervention. The patient is placed in a dental chair in a reclining posture at an angle of 35-50 degrees; a blood pressure is measured, and if the measured systolic pressure is 135-145 mm Hg, the dental intervention is performed. The dental intervention involves blood pressure monitoring, while the conduction anaesthesia is performed with 3% mepivacaine in a combination with the infiltration anaesthesia with 4% articaine with epinephrine 1:200,000 in a quantitative ratio 3:1.

EFFECT: method enables reducing complications and minimising injuries of the dental interventions by using the smoothest possible technique thereof.

3 ex

FIELD: medicine.

SUBSTANCE: method involves performing the following stages: - treating a nerve canal with sodium hypochlorite in the concentration of 0.5-5.25 wt %, in an amount of 1-20 ml for one root canal and activating with ultrasound at frequency 20-40 kHz; both one-stage activation with ultrasound accompanying the treatment, and alternating the sodium hypochlorite treatment and activation with ultrasound every 3-5 sec are possible, - treating with ozonised normal saline in the ozone concentration of 10 mcg to 60 mg per one litre, in an amount of 1-20 ml per 1 root canal and activating with ultrasound at frequency 20-40 kHz, - treating with aqueous chlorhexidine in the concentration of 0.12-2 wt %, in an amount of 1-20 ml per one root canal and activating with ultrasound at frequency 20-40 kHz; the above stages are intermitted with time intervals of no more than 3 minutes, and each stage lasts for 3 to 15 minutes.

EFFECT: high quality of treatment by preventing a post-filling aggravation and reducing the length of periodontal tissue regeneration; the method is easy-to-implement and efficient.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and represents a sustained release solid therapeutic agent containing a combination of praziquantel with emodepside, polyvinylpyrrolidone and/or a polyvinylpyrrolidone derivative in an amount of 10 to 50 wt %, polyvinylpyrrolidone and/or the polyvinylpyrrolidone derivative is a mixture of one short-chain polyvinylpyrrolidone and one polyvinylpyrrolidone or the polyvinylpyrrolidone derivative with longer chains, and at least one excipient in an amount of 5 to 80 wt %.

EFFECT: sustained release of active substances and no lump formation in the gastrointestinal tract if two or more tablets taken.

4 cl, 7 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: therapeutic agent contains anastrozole, poly(lactic-co-glycolic acid), polyvinyl alcohol and D-mannitol. The therapeutic agent represents sub-micron particles and can be presented in the form of capsules, granules, powder, as well as a suspension for injections.

EFFECT: using the developed therapeutic agent enables achieving the therapeutic effect with lower therapeutic doses and making the antitumour therapy more comfortable for the patient.

2 cl, 1 tbl, 2 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to amino amides in the bacteriochlorophyll a series, having the general formula: where n=2, 4, 8, 10, having photo-induced anti-tumour activity, and to a method for production thereof by reacting methyl ether of bacteriopheophorbide a with a diaminoalkane of formula NH2(CH2)nNH2, where n=2, 4, 8, 10, in pyridine.

EFFECT: obtaining highly efficient photosensitisers, amino amides in the bacteriochlorophyll a series based on bacteriochlorin e, having high photo-induced anti-tumour activity.

2 cl, 4 dwg, 11 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to microencapsulation, particularly to a method for producing penicillin microcapsules. According to the method, a microcapsule coating is kappa-carageenan; a weighed amount of kappa-carageenan in acetone is added with a drug powder in the presence of the surfactant E472c; the drug to kappa-carageenan ratio at a dry basis makes from 1:1 to 1:3; after an independent solid phase is formed, carbinol 5 ml and distilled water 1 ml are added very slowly drop by drop; the prepared suspension of the microcapsules is filtered, washed and dried; the encapsulation process takes 15 minutes.

EFFECT: method provides simplifying and accelerating the penicillin microencapsulation in kappa-carageenan.

6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. There are described implanted devices with various versions of biologically active ingredient loading with the version selectable and applicable for creating a prolonged-release profile or a release profile having a low initial ejection of the biologically active ingredient from the implanted device.

EFFECT: there are described the implanted devices with various versions of biologically active ingredient loading.

11 cl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention represents a biologically active composition in the form of an orally dispersible tablet characterised by the fact that its contains dehydroepiandrosterone (DHEA) as an active ingredient and inert excipients: mannitol, sorbitol, manitol, crospovidone, copovidone, a lubricant, an intensive sweetener and a flavouring agent in certain proportions.

EFFECT: invention provides the new form of the biologically active additive of dehydroepiandrosterone.

3 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of microcapsulation, in particular to method of obtaining microcapsules of medications of cephalosporin group. Method is characterised by the fact that as envelope of microcapsules applied is poludanum, powder of medication of cephalosporin group is added to poludanum water solution in presence of surface-active substance E 472c, ratio of poludanum amount and medication of cephalosporin group in counted per dry substance constitutes 3:1, obtained mixture is mixed to complete dissolution of reaction mixture components and carbinol is added drop-by-drop as first precipitator, and then diethyl ether is added as second precipitator, obtained suspension of microcapsules is filtered, washed by acetone, and dried in exsiccator.

EFFECT: method ensures simplification and acceleration of process of obtaining microcapsules of water-soluble medications of cephalosporin group in poludanum, reduction of loss in the process of obtaining microcapsules.

3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to microencapsulation, particularly to a method of producing zinc oxide microcapsules. The method is characterised by that the microcapsule shell used is carrageenan, wherein a weighed portion of zinc oxide in dimethylsulphoxide is mixed with a suspension of carrageenan in butanol in the presence of an E472c surfactant; ethanol is added to the obtained suspension as a precipitant; the obtained suspension is filtered and dried at room temperature.

EFFECT: method provides a simple and faster process of producing zinc oxide microcapsules, reduces losses when producing microcapsules.

3 ex

FIELD: chemistry.

SUBSTANCE: sodium carboxymethylcellulose is used as coating for microcapsules. Charge of fenbendazole, dissolved in dioxane, or dimethylsulphoxide, or dimethylformamide, is dispersed into solution of sodium carboxymethylcellulose in cyclohexanol in presence of surface-active substance E472c, mixing is performed at 1000 rev/s. Weight ratio of fenbendazole and sodium carboxymethylcellulose constitutes 1:3 respectively, after which mixture of butanol and distilled water taken in volume ratio 2:1 respectively is added, obtained suspension of microcapsules is filtered and dried. The process of obtaining fenbendazole microcapsules is realised at 25°C.

EFFECT: simplification and acceleration of the process of obtaining fenbendazole microcapsules in carboxymethylcellulose, reduction of loss in the process of obtaining microcapsules.

3 ex

FIELD: medicine.

SUBSTANCE: invention represents a pharmaceutical composition for treating the HIV infection in the form of a solid dosage form, containing at least one HIV protease inhibitor in a therapeutically effective amount specified in a group of nelfinavir, sacvinavir, tipranavir, darunavir, indinavir, ritonavir, lopinavir, palinavir or fosamprenavir, and pharmaceutically acceptable additives differing by the fact that as the pharmaceutically acceptable additives it contains at least one water-insoluble polymer from 0.39 to 28 wt % of the total dosage form, surfactants, excipients up to 100% of the total dosage form, as well as a method of treating the HIV infection.

EFFECT: pharmaceutical composition according to the invention possesses the improved technological properties and improved bioavailability as compared to a prototype therapeutic agent.

10 cl, 4 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: baseline therapy is accompanied by administering "Enterosgel" 1.5-2 hours prior to or 2 hours after a meal or medication intake in the children aged from 5 to 10 years old in an amount of 15 g 2 times a day, aged from 11 to 15 years old in an amount of 15 g 3 times a day for 7 days; "Qudesan" is administered orally with a meal before noon in age-specific doses: from 5 to 7 years old - 10-16 drops (15-24 mg), from 8 to 15 years old - 16-20 drops (24-30 mg), diluted in a small amount of boiled water or any other beverage of room temperature, once a day for 30 days; "Pantogam" is administered orally 15-20 minutes after a meal in age-specific doses: from 5 to 7 years old - 500 mg 2 times a day, from 8 to 15 years old - 500 mg 3 times a day for 30 days; the combined administration of the above preparations is repeated every 6 months.

EFFECT: method enables reducing the risk of partially controlled forms of bronchial asthma considerably by the pronounced positive synergic effect of the above drug preparations.

4 tbl

Up!